Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

7.940 +0.560 (+7.59%)
Official Closing Price Updated: 5:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cybin Inc. Common Shares

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
18 19 Next >
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Partner Receive Required Schedule I License from DEA for First-in-Human Clinical Trial
Via Investor Brand Network
Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial
From Cybin Inc.
Via Business Wire
Is It Safe to Smoke DMT?
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Results of Annual Meeting of Shareholders
Via Investor Brand Network
Cybin Announces Results of Shareholders’ Meeting
From Cybin Inc.
Via Business Wire
Psilocybin Lawsuit Filed in Canada May Boost Global Psychedelics Reform Efforts
Via Investor Brand Network
Topics Lawsuit
Brain Fingerprinting Adolescents Could Predict Future Mental-Health Issues
Via Investor Brand Network
Toronto Addiction Center Gets First-Ever Federal Grant to Study Effects of Magic Mushroom on Depression
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – August 10, 2022 – Toronto’s Center for Addiction and Mental Health (CAMH) just received the first-ever federal grant to study... 
Via FinancialNewsMedia
Topics Supply Chain
BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Unveils Equity Program, Releases Q1 Financial Report
Via Investor Brand Network
Topics Intellectual Property
CORRECTING and REPLACING Cybin Announces Up to USD$35 Million At-The-Market Equity Program
From Cybin Inc.
Via Business Wire
Cybin Inc. Reports First Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Toronto Firm Receives First Federal Government Funding to Study Psilocybin
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Poised to Accelerate Its CYB004 Clinical Development Program
Via Investor Brand Network
New Poll Finds Most Americans Support Research on Psychedelics for Military Members
Via Investor Brand Network
Topics Cannabis
Study Finds That Difficulty Sleeping, Financial Stressors Increase Mental Health Risk in University Students
Via Investor Brand Network
Research Finds Psychedelics May Open Door to Self-Actualization
Via Investor Brand Network
BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO to Participate in Upcoming Canaccord Genuity Growth Conference
Via Investor Brand Network
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Cleared for Historic Study, Begins Enrolling Participants
Via Investor Brand Network
Cybin to Present at the Canaccord Genuity 42nd Annual Growth Conference
From Cybin Inc.
Via Business Wire
Ketamine Ushering in New Era in the Pharmacology Therapies for Neurological Disorders
Palm Beach, FL – July 27, 2022 – For years, ketamine was known for its use as an anesthetic or as a recreational drug. Its ability to provide quick and safe sedation saved many lives during the Vietnam... 
Via FinancialNewsMedia
Topics Law Enforcement
Research Suggests How Individuals Can Control Unwanted Thoughts
Via Investor Brand Network
BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Scheduled Annual Shareholder Meeting
Via Investor Brand Network
Cybin Announces Date of Annual Meeting of Shareholders
From Cybin Inc.
Via Business Wire
What You Should Know, Do Before Investing in Psychedelics Stocks
Via Investor Brand Network
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Completes Acquisition of Largest-Ever DMT Study
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Unlocking ‘New Frontiers of Discovery’ with Kernel Flow
Via Investor Brand Network
House Approves Amendments on Psychedelic Therapy in Defense Spending Measure
Via Investor Brand Network
Online Companies Offering Mental Health Services Come Under Spotlight
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB003 Phase 1/2a Clinical Trial Through Clinilabs Begins Enrollment
Via Investor Brand Network
Clinilabs Drug Development Corporation Begins Enrollment for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
From Clinilabs Drug Development Corporation
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.